Latest Torcetrapib Stories
HOERSHOLM, Denmark and SAN DIEGO, May 4, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced SPC5001 into Phase 1 clinical trials for the treatment of high cholesterol.
HDL cholesterol can transform from good to bad actor in heart disease process .
WALTHAM, Mass., Jan.
Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.
If you're not one of the 17 percent of Americans who have high cholesterol, you may consider yourself healthy overall. New research that shows some good cholesterol can negatively affect your health may change your mind.Conventional wisdom says having high levels of good cholesterol, or HDL, and low levels of bad cholesterol, or LDL, plays a large role in keeping you healthy. A recent study challenges that idea. After reviewing published data on the topic of good versus bad cholesterol,...
Pfizer has reported positive findings from a post hoc sub-analysis of the five-year Treating to New Targets study.
Anthera Pharmaceuticals has reached an agreement with the FDA on a Phase III protocol for varespladib in acute coronary syndrome under the FDA's special protocol assessment procedure.
By Alex Berenson When the U.S. Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients.
By Gene Emery BOSTON (Reuters) - Patients who take Lipitor, a drug used to treat heart patients, are less likely to suffer a second stroke, according to a study paid for by the drug's maker, Pfizer Inc.
NEW YORK (Reuters) - Pfizer Inc. will apply for approval to sell a new heart treatment as a single pill, rather than only in combination with its top selling Lipitor, the New York Times reported on Wednesday, quoting a company executive.